MASS — 908 Devices Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Specialties·USA

Latest market price

10.98

+1.06+10.69%

Overview Short InterestFilings

MASSQT69908 Devices Inc.·NASDAQ

Overview Short InterestFilings

10.98+10.69%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BWAY+0.52%$13.53 SI-0.50%$17.80 MOBI+1.40%$10.86 LAB+2.95%$0.73 MLAB+1.48%$127.14 QDEL+2.97%$11.09 STE-0.89%$208.04 ALC-1.69%$65.18

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	20.31%	Shs Outstand	41.03M	Perf Week	17.43%

Market Cap	450.48M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	-11.63%	Shs Float	30.79M	Perf Month	8.93%

Enterprise Value	352.48M	PEG	-	EPS next Q	-0.16	Inst Own	-	Short Float	9.12%	Perf Quarter	27.97%

Income	-35.00M	P/S	7.51	EPS this Y	9.47%	Inst Trans	-	Short Ratio	7.42	Perf Half Y	83.31%

Sales	60.00M	P/B	3.55	EPS next Y	47.21%	ROA	-17.46%	Short Interest	2.81M	Perf YTD	109.14%

Book/sh	3.10	P/C	4.42	EPS next 5Y	-	ROE	-25.50%	52W High	11.25 -2.40%	Perf Year	78.25%

Cash/sh	2.49	P/FCF	-	EPS past 3/5Y	-	ROIC	-18.70%	52W Low	5.03 118.29%	Perf 3Y	73.19%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	6.01% 15.71%	Gross Margin	49.79%	Volatility	5.82% 5.08%	Perf 5Y	-69.44%

Dividend TTM	-	EV/Sales	5.87	EPS Y/Y TTM	55.19%	Oper. Margin	-46.01%	ATR (14)	0.56	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.38	Sales Y/Y TTM	0.00%	Profit Margin	-56.68%	RSI (14)	65.10	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	2.67	EPS Q/Q	11.11%	SMA20	6.67%	Beta	0.62	Target Price	12.00

Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	23.08%	SMA50	20.34%	Rel Volume	1.72	Prev Close	9.92

Employees	172	LT Debt/Eq	0.04	Earnings	Nov 09	SMA200	47.70%	Avg Volume	400.23K	Price	10.98

IPO Date	Dec 18, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-125.35% 4.55%	Net Debt/EBITDA	1.97	Volume	689,788	Change	10.69%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-12-26	Reiterated	Stifel Nicolaus		$12
Aug-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-13-24	Downgrade	Leerink Partners	Outperform → Market Perform

Latest News· Times ET

Sep-11-26

Sep-11-2611:49PM

Comparing 908 Devices (NASDAQ:MASS) & Plexus (NASDAQ:PLXS)defenseworld.net

Sep-10-26

Sep-10-2604:09AM

Canaccord Genuity Initiates Coverage On 908 Devices with Buy Rating, Announces Price Target of $13.5Benzinga

Sep-03-26

Sep-03-2611:29PM

BlackRock Inc. Takes $16.91 Million Position in 908 Devices Inc. $MASSdefenseworld.net

Sep-01-26

Sep-01-2603:00AM

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposiumbusinesswire.com

Aug-30-26

Aug-30-2603:05PM

908 Devices Inc. (MASS) Presents at 17th Annual Midwest IDEAS Conference - SlideshowSeekingAlpha

Aug-29-26

Aug-29-2606:02PM

908 Devices Raises 2026 Outlook as Handheld Detection Demand Acceleratesmarketbeat.com

Aug-21-26

Aug-21-2604:25PM

Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvaluedgurufocus.com

Aug-18-26

Aug-18-2606:22AM

908 Devices (NASDAQ:MASS) Qualifies for Minervini Trend Template and High-Growth Momentum ScreenChartMill

Aug-17-26

Aug-17-2606:02PM

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detectionmarketbeat.com

Aug-14-26

Aug-14-2611:02PM

908 Devices Eyes Growth in Handheld Drug and Chemical Detection Marketmarketbeat.com

Aug-13-26

Aug-13-2604:15AM

908 Devices Q2: Another Solid Reportseekingalpha.com

Aug-12-26

Aug-12-2611:07AM

908 Devices: Mission Critical Devices Drive Growthseekingalpha.com

03:00AM

908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conferencebusinesswire.com

Aug-11-26

Aug-11-2610:27AM

908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcriptseekingalpha.com

07:06AM

908 Devices Q2 Earnings Call Highlightsmarketbeat.com

Company

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	60	56	60	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	31	29	30	—	—	—	—	—	—
Gross Profit	30	27	30	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	39	37	0	—	—	—	—	—	—
Research and Development	13	14	25	—	—	—	—	—	—
Other Operating Expense	6	0	82	—	—	—	—	—	—
Operating Income	-29	-24	-77	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-6	-9	4	—	—	—	—	—	—
Net Income Before Taxes	-35	-33	-72	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-35	-37	-72	—	—	—	—	—	—
Net Income From Continuing Operations	-35	-33	-72	—	—	—	—	—	—
Net Income	-35	-37	-72	—	—	—	—	—	—
EPS (Recurring)	-0.93	-1.01	-2.12	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.93	-1.01	-2.12	—	—	—	—	—	—
EPS (Diluted)	-0.95	-0.94	-2.12	—	—	—	—	—	—
EBITDA	-31	-29	-44	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	6.95	3.38	1.25	—	—	—	—	—	—
Gross Margin	50.00	48.21	50.00	—	—	—	—	—	—
Operating Margin	-48.33	-42.86	-128.33	—	—	—	—	—	—
Net Margin	-58.33	-66.07	-120.00	—	—	—	—	—	—
Shares Outstanding	38	36	34	—	—	—	—	—	—
Market Capitalization	417	189	75	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kenneweg John	SVP, Sales & Product Marketing	Sep 17 '26	Sale	10.22	5,257	53,727	57,784	Sep 17
Kenneweg John	SVP, Sales & Product Marketing	Sep 17 '26	Option Exercise	0.96	5,257	5,047	63,041	Sep 17
Kenneweg John	SVP, Sales & Product Marketing	Sep 16 '26	Option Exercise	0.96	21,399	20,543	79,183	Sep 17
Kenneweg John	SVP, Sales & Product Marketing	Sep 16 '26	Sale	10.11	21,399	216,344	57,784	Sep 17
Kenneweg John	SVP, Sales & Product Marketing	Sep 15 '26	Sale	10.00	1,000	10,000	57,784	Sep 17
Kenneweg John	SVP, Sales & Product Marketing	Sep 15 '26	Option Exercise	0.96	1,000	960	58,784	Sep 17
Brown Christopher D.	Director	Sep 02 '26	Sale	10.58	30,000	317,400	775,559	Sep 04
Griffith Joseph H. IV	Chief Financial Officer	Aug 25 '26	Sale	10.95	11,459	125,476	121,497	Aug 27
AWM Investment Company, Inc.	10% Owner	Aug 21 '26	Sale	10.61	41,578	441,159	4,779,773	Aug 24
AWM Investment Company, Inc.	10% Owner	Aug 20 '26	Sale	10.52	8,422	88,638	4,821,351	Aug 24
Knopp Kevin J.	President and CEO	Aug 17 '26	Sale	10.35	20,000	207,000	555,968	Aug 17
Knopp Kevin J.	President and CEO	Aug 13 '26	Sale	10.06	7,622	76,677	575,968	Aug 17
Knopp Kevin J.	President and CEO	Aug 12 '26	Sale	10.07	2,747	27,662	583,590	Aug 12
Brown Christopher D.	Director	Aug 11 '26	Sale	9.23	8,358	77,144	805,559	Aug 12
Knopp Kevin J.	President and CEO	Aug 11 '26	Sale	9.90	145,918	1,444,330	586,337	Aug 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.